Rigel Pharmaceuticals Completes VEPPANU Licensing Deal for $70M

Key Highlights

• Rigel Pharmaceuticals completed the License Agreement for VEPPANU (vepdegestrant).
• The company acquired exclusive, global rights to develop, manufacture, and commercialize VEPPANU worldwide.
• The agreement was made with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc., and Pfizer Inc.
• Rigel made a one-time upfront payment of $70.0 million to the licensors.
• The transaction became effective after the early termination of the Hart-Scott-Rodino waiting period and other closing conditions were met.